Injectable AIDS drug may work 'as well' as pills: study

At present people have no ­option but to take lifelong, daily doses of antiretroviral therapy which keeps HIV under control, but does not kill it

PUBLISHED : Monday, 24 July, 2017, 10:49pm
UPDATED : Monday, 24 July, 2017, 10:49pm

A two-drug cocktail injected every month or two may be just as effective as a daily pill at keeping the Aids virus under control, according to a new study.

At present people have no ­option but to take lifelong, daily doses of antiretroviral therapy (ART) which keeps HIV under control, but does not kill it.

People who forget to take their medication run the risk of the virus rebounding to make them ill, or developing resistance to the drugs they were using – which would require a more expensive replacement.

UN report proclaims ‘scales have tipped’ in battle against Aids with one million deaths in 2016

In an ongoing study, nearly 300 HIV positive people were given a course of daily pills to bring the virus under control. Once achieved, some continued taking oral treatment while the rest were moved onto the prototype, injectable ARV, administered every four or eight weeks.

At 96 weeks, the virus was still subdued in 84 per cent of the pill group, 87 per cent in the injectable group, and 94 per cent in the eight-weekly group.

The results were published in The Lancet medical journal to ­coincide with an HIV science ­conference in Paris by the International Aids Society.

In 2016, there were some 36.7 million people with HIV with 19.5 million having access to ART, according to UNAIS.

“The introduction of single-tablet medication represented a leap forward in ART dosing, and long-active antiretroviral injections may represent the next ­revolution in HIV therapy by providing an option that circumvents the burden of daily dosing,” said study co-author David Margo of Viiv Healthcare, a pharmaceutical company involved in developing the injectable drug. “Adherence to medication remains an important challenge in HIV treatment.”

Also involved in the study is Janssen Sciences, a company in the Johnson & Johnson group.

Last week, the UN warned that countries must halt the rise of Aids drug resistance to prevent a swell in new infections and deaths and spiralling treatment costs.

Diabetes takes a growing toll on Africa, as rising incomes get spent on junk food: report

Viruses can become resistant to drugs when people take incorrect doses of their prescribed medication. Resistant strains can also be contracted directly from other people.

Some in the trial group experienced mild or moderate pain at the injection site. Two subjects wanted to stop getting the shots, which contain a mix of cabotegravir and rilpivirine.

People in all the groups suffered other side effects, including diarrhoea and headaches.

“Trials are ongoing and are needed to confirm the results,” the researchers said a statement.

The experiments were conducted in the United States, ­Germany, Canada, Spain, France and Germany.